SHTDY (Sinopharm Group Co) Ending Cash Position: $6,928 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHTDY Sinopharm Group Co Ltd SHTDY
69 GF Score
Price $11.20
GF Value $13.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Ending Cash Position?

Sinopharm Group Co SHTDY -0.09% 69 Ending Cash Position is $6,928 Mil as of Dec. 2025. GuruFocus rates SHTDY with a GF Score™ of 69/100 and a GF Value™ of $13.31 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co's Ending Cash Position for the quarter that ended in Dec. 2025 was $6,928 Mil.

Sinopharm Group Co's quarterly Ending Cash Position declined from Dec. 2024 ($7,460 Mil) to Jun. 2025 ($4,908 Mil) but then increased from Jun. 2025 ($4,908 Mil) to Dec. 2025 ($6,928 Mil).

Sinopharm Group Co's annual Ending Cash Position declined from Dec. 2023 ($8,937 Mil) to Dec. 2024 ($7,460 Mil) and declined from Dec. 2024 ($7,460 Mil) to Dec. 2025 ($6,928 Mil).

Sinopharm Group Co Ending Cash Position Related Terms

Sinopharm Group Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Ending Cash Position Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,834.26 7,920.83 8,936.52 7,459.91 6,928.12

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,936.52 5,972.92 7,459.91 4,907.55 6,928.12
SHTDY
69GF Score
Sinopharm Group Co Ltd SHTDY
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sinopharm Group Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7711.462+-783.342
=6,928

Sinopharm Group Co's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5003.143+1924.977
=6,928

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $6,928 Mil mean?
Sinopharm Group Co (SHTDY) has a Ending Cash Position of $6,928 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Ending Cash Position too high?
Sinopharm Group Co's current Ending Cash Position is $6,928 Mil. Overall, Sinopharm Group Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Ending Cash Position compare to MCK and CAH?
Sinopharm Group Co's Ending Cash Position of $6,928 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Distribution company?
A good Ending Cash Position depends on the Medical Distribution industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Ending Cash Position is $6,928 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.31, compared to a current price of $11.20 — trading 15.9% below its estimated fair value. The current Ending Cash Position is $6,928 Mil. Sinopharm Group Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Ending Cash Position is $6,928 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $11.20 is trading 15.9% below its estimated GF Value™ of $13.31. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Ending Cash Position: $6,928 Mil
  • GF Value™: $13.31 vs. price of $11.20 (15.9% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
69GF Score

Get the complete analysis for SHTDY

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.20
Price
$13.31
GF Value